Business
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
- First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million - First quarter DAYBUE™ (trofinetide) net product sales of $75.9 million SAN
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\n- First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million\n\n\n- First quarter DAYBUE™ (trofinetide) net product sales of $75.9 million\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.\n\n\n“In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% revenue growth year over year, primarily due to the addition of our second commercial product, DAYBUE for the treatment of Rett syndrome, combined with growth in market share of NUPLAZID for the treatment of Parkinson’s disease psychosis,” said Steve Davis, Chief Executive Officer. “In addition, we are executing on our plans to bring DAYBUE to markets outside the U.S., continuing to enroll our late-stage trials in Prader-Willi syndrome and Alzheimer’s disease psychosis, and utilizing our financial strength to support our early-stage pipeline and business development opportunities.”\n\n\nCompany Updates\n\n\n\nSeven posters accepted for presentation at the International Rett Syndrome Foundation’s Scientific Meeting to be held on June 18-19, 2024. These will include, among other topics, two encore presentations discussing outcomes from LILAC-2™, as well as findings from exit interviews with caregivers of individuals living with Rett syndrome who participated in the DAYBUE clinical trials supporting its approval. The company will also present a poster with additional real world patient and caregiver experiences from an analysis of an ongoing post marketing observational study.\n\n\n\nThe Journal of Alzheimer’s Disease published favorable results from a Phase 3b trial evaluating the safety and tolerability of NUPLAZID (pimavanserin) in patients with neuropsychiatric symptoms related to neurodegenerative diseases 60 years of age and older. NUPLAZID was well-tolerated in this elderly, frail population, with a similar rate of treatment-emergent adverse events to the placebo group and did not impact motor or cognitive function versus placebo.\n\n\n\nAppointed Elizabeth H.Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development. Dr. Thompson joined Acadia’s executive leadership team.\n\n\n\nFinancial Results\n\n\nRevenues\n\n\nTotal revenues, comprised of net product sales from NUPLAZID and DAYBUE...